Navigation Links
Anavex appoints Dr. Dimitri Goundis to lead Clinical Development
Date:4/16/2008

GENEVA, Switzerland, April 16 /PRNewswire-FirstCall/ - Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today announced the appointment of Dr. Dimitri Goundis as Project Director of Clinical Development as the company prepares to enter human clinical trials with its lead Alzheimer's compound within the next 12 months.

Dr. Goundis has more than 20 years experience in the management of clinical trials, including leadership positions at Speedel AG (SWX: SPPN), The Medicines Company (NASDAQ: MDCO) and Roche (SWX: ROG). He has successfully led the development of several medications currently on the market, including SPP 100 (Tekturna/Rasilez), which was licensed by Novartis (NYSE: NVS) and subsequently approved by the US Food and Drug Administration (FDA), the European Commission and the Swiss Agency for Therapeutic Products (Swissmedic), Switzerland's drug and device regulatory agency.

Dr. Goundis will lead the clinical development of ANAVEX's robust pipeline. He will establish a clinical development team as well as select and manage the contract research organizations that will work with ANAVEX to move its drug candidates through clinical trials in preparation for submission to the FDA and other regulatory agencies. Dr. Goundis will be responsible for medicinal chemistry and for galenics, which pertains to the formulation of therapeutic agents into palatable or otherwise practically useful formulations.

"We are honored to welcome Dr. Goundis as a key member of ANAVEX's senior management team and be
'/>"/>

SOURCE Anavex Life Sciences Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
2. Anavex strengthens Board of Directors
3. Anavex advances drug candidate for treatment of Alzheimers disease
4. Phytomedics Inc. Appoints Dr. Laurie Smaldone Alsup, MD., as President and Chief Executive Officer
5. Metabolex Appoints Donald Hill as Chief Financial Officer
6. Biopure Appoints New Independent Auditor
7. Indivumed Appoints Annette Kassen as Vice President Clinical Research
8. ADVENTRX Appoints Vice President of Manufacturing
9. Egenix, Inc. Appoints Dr. Daniel Petrylak Chairman of Scientific Advisory Board
10. NanoLogix Inc. Provides Financial Update, Appoints Bert Pharis as New Director
11. Observant LLC Appoints Two New Directors to the Senior Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 25, 2014 Silicon Valley Electronic ... with RPM Alliance , provider of clinical research ... With the latest addition to its CRO Partnership Program, ... EDC system to India. , “We have found ... and customizable EDC platform which is both user friendly ...
(Date:11/26/2014)... Boston, MA (PRWEB) November 26, 2014 ... and collaboration company is proud to announce that Darren ... Development and Sales. Darren will drive the ... and positive customer experience. , Darren brings ... He has held key roles in channel operations, from ...
(Date:11/26/2014)... -- Theravalues Corporation annuncia con orgoglio il lancio di ... Hi Europe 2014 (dal 2 al 4 dicembre, ... curcumina con la maggiore biodisponibilità di sempre, con una ... dalle norme europee. La curcumina è un ... Curcuma longa ) che è stata associata con attività ...
(Date:11/24/2014)... 24, 2014 VolitionRx Limited (OTCQB: VNRX), ... cancer and other conditions, today announced that data from its ... for Business BioWin Day 2014, being held November 26, 2014 ... from VolitionRx,s lung cancer pilot study, the samples for which ... Universitaire (CHU) de Liege in Belgium . ...
Breaking Biology Technology:RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2SoundConnect Appoints Director of Channel Development & Sales 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6
... Switzerland, August 19 Arpida Ltd,(SIX: ARPN) announced today its financial results ... Key events 2009 to date, - Regulatory setback for ... under review, - Company restructuring completed, , ... June 2009 , CFO Harry Welten, MBA, commented: ...
... , WESTON, Fla., Aug. 19 In keeping with ... of families, America n Scientific Resources ... obtained from Safeguard Medical Technologies, LLC exclusive worldwide rights to sell ... and the Disintegrator Plus(TM). , , All ...
... , , LONDON, Aug. 19 ... the introduction of improved drugs to treat the disease. As healthcare ... companies conducting research on diabetes vaccines. If they succeed, the entire ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , , ...
Cached Biology Technology:Arpida Reports Interim Results For Six Months to 30 June 2009 2American Scientific Resources To Be Exclusive Seller of World's Only FDA Approved Home Needle Destruction Device 2American Scientific Resources To Be Exclusive Seller of World's Only FDA Approved Home Needle Destruction Device 3Emergence of Newer Drug Classes to Treat Diabetes and Co-morbidities Key to Market Expansion, Reveals Frost & Sullivan 2Emergence of Newer Drug Classes to Treat Diabetes and Co-morbidities Key to Market Expansion, Reveals Frost & Sullivan 3
(Date:11/15/2014)... 13, 2014  While we may still be a few ... in "Star Trek" to gain instant access to all that ... with smartphones and tablets for monitoring and measuring our health ... This may seem a tad Orwellian to some, but a ... of these technological opportunities into their healthcare regime. ...
(Date:11/11/2014)... , Nov. 11, 2014  Forensicon, Inc., a ... is pleased to announce the promotion of Yaniv ... of Digital Forensics. In Schiff,s new role as Director, ... team of digital forensics examiners and provide leadership within ... Photo - http://photos.prnewswire.com/prnh/20141110/157719 Schiff ...
(Date:11/7/2014)... by Dr. Debra Auguste, associate professor, biomedical engineering, ... City College of New York, have identified a ... one of the most aggressive forms of breast ... a high mortality rate owing to aggressive proliferation ... options. However, Professor Auguste,s team, discovered the overexpression ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... have genetic evidence suggesting the antioxidant drugs currently ... the common cold can also help prevent and ... stressa culprit in driving tumor growth. ... loss of the tumor suppressor protein Caveolin-1 (Cav-1) ...
... the increasing incidence of antifungal-resistant infections, according to a ... . The essential oil shows a potent antifungal effect ... nail infections. Scientists from the University of Coimbra ... L,Hr shrub that grows in southern Portugal. The oil ...
... progressive trajectory is one of the most deeply-entrenched assumptions ... popular media by showing cavemen speaking in grunts and ... But is this assumption correct? Were the earliest ... a paper published in the latest issue of ...
Cached Biology News:Jefferson researchers provide genetic evidence that antioxidants can help treat cancer 2Jefferson researchers provide genetic evidence that antioxidants can help treat cancer 3Lavender oil has potent antifungal effect 2Earliest humans not so different from us, research suggests 2Earliest humans not so different from us, research suggests 3